Department of Obstetrics and Gynecology, University of Chicago, Chicago, IL, United States.
Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland, OR, United States.
Contraception. 2021 Jun;103(6):444-449. doi: 10.1016/j.contraception.2021.02.013. Epub 2021 Feb 28.
Assess the relationship between parity and prior route of delivery to levonorgestrel 52 mg intrauterine system (IUS) expulsion during the first 72 months of use.
We evaluated women enrolled in the ACCESS IUS multicenter, Phase 3, open-label clinical trial of the Liletta levonorgestrel 52 mg IUS. Investigators evaluated IUS presence at 3 and 6 months after placement and then every 6 months and during unscheduled visits. We included women with successful placement and at least one follow-up assessment. We evaluated expulsion rates based on obstetric history; for prior delivery method subanalyses, we excluded 12 participants with missing delivery data. We determined predictors of expulsion using multivariable regression analyses.
Of 1714 women with IUS placement, 1710 had at least one follow-up assessment. The total population included 986 (57.7%) nulliparous women. Sixty-five (3.8%) women experienced expulsion within 72 months, 50 (76.9%) within the first 12 months. Expulsion rates among nulliparous women (22/986 [2.2%]) or parous women with any pregnancy ending with a Cesarean delivery (6/195 [3.1%]) differed from parous women who only experienced vaginal deliveries (37/517 [7.2%]) (p < 0.001). In multivariable regression, obesity (adjusted odds ratio [aOR] 2.2, 95% confidence interval [CI] 1.3-3.7), parity (aOR 2.2, 95% CI 1.2-4.1), and non-white race (aOR 1.8, 95% CI 1.1-3.2) predicted expulsion. Among parous women, obesity (aOR 2.2, 95% CI 1.2-4.2) increased the odds and having ever had a cesarean delivery (aOR 0.4, 95% CI 0.1-0.9) decreased the odds of expulsion.
IUS expulsion occurs in less than 4% of users over the first 6 years of use and occurs mostly during the first year. Expulsion is more likely among obese and parous women.
Levonorgestrel 52 mg intrauterine system expulsion occured more commonly in parous than nulliparous women; the increase in parous women is primarily in women who had vaginal deliveries only. The association between obesity, delivery route, and IUS expulsion needs further elucidation.
评估产次和既往分娩方式与左炔诺孕酮 52mg 宫内节育系统(IUS)在使用的前 72 个月内脱落之间的关系。
我们评估了参加 ACCESS IUS 多中心、3 期、左炔诺孕酮 52mg Liletta IUS 开放性标签临床试验的女性。研究人员在放置后 3 个月和 6 个月以及之后每 6 个月和非计划性就诊时评估 IUS 的存在情况。我们纳入了具有成功放置和至少一次随访评估的女性。我们根据产科史评估脱落率;对于既往分娩方式的亚组分析,我们排除了 12 名分娩数据缺失的参与者。我们使用多变量回归分析确定脱落的预测因素。
在 1714 名接受 IUS 放置的女性中,有 1710 名至少有一次随访评估。总人群包括 986 名(57.7%)未产妇。65 名(3.8%)女性在 72 个月内发生脱落,其中 50 名(76.9%)在最初 12 个月内发生脱落。未产妇(22/986 [2.2%])或仅经历过阴道分娩的经产妇女中任何妊娠结局为剖宫产的(6/195 [3.1%])脱落率与经历过阴道分娩的经产妇女(37/517 [7.2%])不同(p<0.001)。在多变量回归中,肥胖(调整后优势比[aOR] 2.2,95%置信区间[CI] 1.3-3.7)、产次(aOR 2.2,95% CI 1.2-4.1)和非白种人种族(aOR 1.8,95% CI 1.1-3.2)预测脱落。在经产妇女中,肥胖(aOR 2.2,95% CI 1.2-4.2)增加了脱落的可能性,而曾经进行过剖宫产(aOR 0.4,95% CI 0.1-0.9)降低了脱落的可能性。
在使用的前 6 年中,IUS 脱落发生在不到 4%的使用者中,并且大多发生在最初的 1 年内。肥胖和经产妇中更易发生脱落。
左炔诺孕酮 52mg 宫内节育系统脱落更常见于经产妇而非初产妇;经产妇的增加主要发生在仅经历过阴道分娩的女性中。肥胖、分娩方式和 IUS 脱落之间的关联需要进一步阐明。